EXEL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EXEL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Exelixis's operating assets for the quarter that ended in Sep. 2024 was $1,771 Mil. Exelixis's operating liabilities for the quarter that ended in Sep. 2024 was $490 Mil. Exelixis's Total Assets for the quarter that ended in Jun. 2024 was $2,773 Mil. Therefore, Exelixis's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.46.
The historical data trend for Exelixis's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exelixis Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Scaled Net Operating Assets | Get a 7-Day Free Trial | 0.62 | 0.38 | 0.37 | 0.52 | 0.48 |
Exelixis Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Scaled Net Operating Assets | Get a 7-Day Free Trial | 0.46 | 0.49 | 0.46 | 0.47 | 0.46 |
For the Biotechnology subindustry, Exelixis's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Exelixis's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Exelixis's Scaled Net Operating Assets falls into.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Exelixis's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as
Scaled Net Operating Assets (SNOA) | (A: Dec. 2023 ) | ||||
= | (Operating Assets (A: Dec. 2023 ) | - | Operating Liabilities (A: Dec. 2023 )) | / | Total Assets (A: Dec. 2022 ) |
= | (1947.055 | - | 488.501) | / | 3071.489 |
= | 0.47 |
where
Operating Assets | (A: Dec. 2023 ) | ||
= | Total Assets | - | Cash, Cash Equivalents, Marketable Securities |
= | 2942.357 | - | 995.302 |
= | 1947.055 |
Operating Liabilities | (A: Dec. 2023 ) | ||||
= | Total Liabilities | - | Long-Term Debt & Capital Lease Obligation | - | Short-Term Debt & Capital Lease Obligation |
= | 678.445 | - | 189.944 | - | 0 |
= | 488.501 |
Exelixis's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as
Scaled Net Operating Assets (SNOA) | (Q: Sep. 2024 ) | ||||
= | (Operating Assets (Q: Sep. 2024 ) | - | Operating Liabilities (Q: Sep. 2024 )) | / | Total Assets (Q: Jun. 2024 ) |
= | (1771.115 | - | 490.412) | / | 2773.121 |
= | 0.46 |
where
Operating Assets | (Q: Sep. 2024 ) | ||
= | Total Assets | - | Cash, Cash Equivalents, Marketable Securities |
= | 2960.276 | - | 1189.161 |
= | 1771.115 |
Operating Liabilities | (Q: Sep. 2024 ) | ||||
= | Total Liabilities | - | Long-Term Debt & Capital Lease Obligation | - | Short-Term Debt & Capital Lease Obligation |
= | 684.857 | - | 194.445 | - | 0 |
= | 490.412 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Exelixis's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey Hessekiel | officer: EVP and General Counsel | 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Patrick J. Haley | officer: Sr. Vice President, Commercial | 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Dana Aftab | officer: CSO/EVP Disc & Trans Research | EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502 |
George Poste | director | 515 GALVESTON DR, REDWOOD CITY CA 94063 |
Maria C Freire | director | C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101 |
Christopher J. Senner | officer: EVP and CFO | 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Jack L Wyszomierski | director | SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000 |
David Edward Johnson | director | 590 MADISON AVENUE, NEW YORK NY 10022 |
Julie Smith | director | C/O RAPTOR PHARMACEUTICAL CORP, 9 COMMERCIAL BLVD, SUITE 200, NOVATO CA 94949 |
Stelios Papadopoulos | director | 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020 |
Alan M Garber | director | 3355 MILTON COURT, MOUNTAIN VIEW CA 94040 |
Amy C. Peterson | officer: EVP Prod Dev & Med Aff & CMO | C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108 |
Bob Oliver | director | C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Caligan Partners Lp | director, other: See Remarks | 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022 |
Tomas J. Heyman | director | C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By Business Wire • 08-28-2024
By Business Wire • 10-29-2024
By Business Wire • 05-20-2024
By GuruFocus Research • 05-24-2024
By Business Wire • 07-23-2024
By GuruFocus News • 10-30-2024
By Business Wire • 08-06-2024
By Business Wire • 02-27-2024
By Business Wire • 08-06-2024
By GuruFocus Research • 03-04-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.